This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

Pipeline OverviewNeuroendocrine TumorsGlioblastomaOsteosarcoma / Bone MetastasesFolate Receptor Alpha + TumorsPartnering Opportunities

Glioblastoma

The therapeutic DP-3311 (n.c.a. 177Lu-TTM*)

Glioblastoma is one of the most malignant types of primary brain tumors. It is a rare tumor, with about 3 new cases per 100,000 individuals per year with a poor prognosis.1 Even though surgery, chemotherapy, and radiotherapy have advanced over the last decade, resulting in a gradual improvement in the survival and quality of life of glioblastoma patients, the prognosis remains depressing.2

Glioblastoma is a complex tumor which is very difficult to treat. Surgery is rarely curative as the tumor cells infiltrate the surrounding tissue and the blood-brain barrier places a limitation on medical therapies.

In conjunction with Helmholtz Zentrum München (HZM), ITM is developing a novel n.c.a. 177Lu-TTM* for intra-cavitary immunoradiotherapy (iRIT) in patients suffering from glioblastoma. N.c.a. 177Lu-TTM* consists of two molecular components – firstly, n.c.a. Lutetium-177 (EndolucinBeta®), a synthetic, low-energy beta-emitting isotope of Lutetium, and secondly, a nondisclosed tumor-targeting molecule TTM*, specifically targeting glioblastoma cells.

HZM is currently leading a Phase I study in three German neurosurgical centers. Upon completion of the study, ITM has the option to take n.c.a 177Lu-TTM* into full clinical development.

 

*TTM = Tumor-Targeting Molecule; nondisclosed

1 Gallego, 2015, Current Oncology 22(4): e273–e281 and
  Bahadur et al., 2019, Oncology Reviews 13(2): 417
2 Gallego, 2015, Current Oncology 22(4): e273–e281 and
  Weller et al., 2013, Neuro-Oncology 15(1): 4–27